-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On December 23, Junshi Biological issued an announcement stating that its application for clinical trial of JS001sc injection was accepted by the China Food and Drug Administration
JS001sc targets human PD-1, binds to PD-1 with high affinity, and selectively blocks the binding of PD-1 to the ligands PD-L1 and PD-L2, thereby activating T lymphocytes and improving the proliferation and cell proliferation of lymphocytes.
Pre-clinical in vivo pharmacodynamic tests have shown that JS001sc has a significant tumor-inhibiting effect in animal models when administered by subcutaneous injection.
With the gradual popularization of the concept of "chronic disease management" in tumor immunotherapy, compared with frequent visits to the hospital for several hours of intravenous injection, shorter time subcutaneous injections are more attractive, making immunotherapy more accessible It also helps to further reduce the burden of medical insurance and reduce the direct and indirect medical costs of patients’ families and society as a whole
At present, among more than ten kinds of PD-(L)1 antibodies that have been marketed worldwide, only Envolimab injection (trade name: Envida) is administered by subcutaneous injection, and the rest are administered by intravenous injection.
